Signature Wealth Management Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$937K Sell
1,019
-24
-2% -$24.3K 0.47% 39
2025
Q4
$1.12M Buy
1,043
+4
+0.4% +$3.83K 0.55% 37
2025
Q3
$793K Buy
1,039
+61
+6% +$45.4K 0.42% 48
2025
Q2
$763K Buy
978
+197
+25% +$153K 0.44% 45
2025
Q1
$645K Buy
781
+270
+53% +$225K 0.42% 45
2024
Q4
$395K Buy
511
+100
+24% +$82.8K 0.27% 67
2024
Q3
$364K Buy
411
+123
+43% +$111K 0.26% 70
2024
Q2
$261K Buy
+288
New +$230K 0.2% 85

Other funds holding LLY

Signature Wealth Management Partners's LLY Position: Q1 2026 in Review

Signature Wealth Management Partners reduced its Eli Lilly (LLY) stake by 2.3% in Q1 2026, selling an estimated $24.3K and leaving 1,019 shares worth $937K. The position accounts for 0.47% of the portfolio, ranked #39.

Signature Wealth Management Partners first reported a position in LLY in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.12M in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Signature Wealth Management Partners held 1,019 shares of Eli Lilly worth $937K as of Q1 2026.
  • Signature Wealth Management Partners sold 24 Eli Lilly shares in Q1 2026, an estimated $24.3K.
  • Eli Lilly made up 0.47% of Signature Wealth Management Partners's portfolio in Q1 2026, its #39 holding.
  • Signature Wealth Management Partners first reported a position in Eli Lilly in Q2 2024 and has held it in 8 quarters since.
  • Signature Wealth Management Partners's Eli Lilly position peaked at $1.12M in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Signature Wealth Management Partners's 13F filing for Q1 2026, filed 21 Apr 2026.